prodchem
Aug 28, 2026
Eli Lilly’s aggressive biotechnology acquisition strategy in 2026 offers a useful lesson for the agrochemical industry: large companies do not necessarily need to build every new technology internally when they can acquire specialized platforms, scientific teams and early-stage assets from focused innovators.
Lilly has spent billions of dollars this year expanding beyond its core metabolic franchises, acquiring or agreeing to acquire biotechnology companies across oncology, immunology, genetic medicine, neuroscience and infectious disease. By June 2026, Lilly reported $13.3 billion in cash payments related to business-development activity, driven primarily by acquisitions including Centessa, Kelonia, Orna, Ventyx and Ajax.
The strategy provides a potential template for agrochemical companies facing their own innovation challenge.
Rather than relying exclusively on internal discovery programs, major crop-science companies could use targeted acquisitions to obtain new biological platforms, formulation technologies, computational tools and specialized scientific talent.
One of the most important characteristics of Lilly's 2026 acquisition strategy is the emphasis on technology platforms.
The company has not simply purchased commercial-stage medicines.
It has targeted biotechnology companies whose underlying technologies could potentially produce multiple future products.
The acquisition of Kelonia Therapeutics, for example, gives Lilly access to an in-vivo gene-placement system designed to generate CAR-T cells inside the patient's body. Lilly said the platform could have applications beyond the lead multiple-myeloma program.
Similarly, the acquisition of Ajax Therapeutics provided Lilly with AJ1-11095, a Phase 1 Type II JAK2 inhibitor, while also adding expertise in structural biology and computational structure-based drug discovery.
This is the distinction that matters for agriculture.
A crop-science company does not necessarily need to acquire a single pesticide product.
It could acquire the technology capable of generating the next group of products.
Agricultural innovation is becoming increasingly multidisciplinary.
New crop-protection solutions can involve:
Biologicals
RNA-based technologies
Novel modes of action
Precision formulation
Computational chemistry
Microbial platforms
Seed-treatment technologies
Digital agriculture
Controlled-release systems
New delivery technologies
Building expertise in every one of these areas internally can be expensive and slow.
A targeted acquisition can provide immediate access to a specialized team and technology platform.
This is where Lilly's model becomes relevant.
The pharmaceutical company identifies a scientific capability that could strengthen its long-term pipeline, evaluates an emerging biotech's technology and then uses its larger development infrastructure to scale the opportunity.
The underlying business challenge is similar.
Pharmaceutical companies face patent expirations, clinical attrition and the need to replenish future pipelines.
Agrochemical companies face their own version of the innovation gap.
Existing active ingredients eventually face:
Resistance development
Regulatory restrictions
Environmental scrutiny
Loss of exclusivity
Generic competition
Changing pest pressures
New sustainability requirements
This means agricultural companies need a continuous supply of differentiated technologies.
Internal R&D remains essential, but external innovation can accelerate the process.
The Ajax transaction provides one of the clearest examples.
Lilly agreed to acquire Ajax for up to $2.3 billion, including upfront and milestone payments. Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor being studied for myelofibrosis and polycythemia vera.
But Lilly was also acquiring the scientific expertise behind the program.
Ajax was founded around specialists in cancer and structural biology and worked with Schrödinger on computational structure-based drug discovery.
For agrochemical companies, the equivalent could be a small biotechnology or chemistry company with expertise in a difficult area such as:
Novel biological mechanism + computational design + formulation + field validation
The acquisition would bring together the people and intellectual property required to continue developing the technology.
A key lesson from Lilly is that acquisition does not necessarily have to happen after a product reaches commercialization.
Early-stage assets can be attractive if the underlying science is differentiated.
Lilly acquired companies with assets at different development stages, including programs still undergoing early clinical evaluation.
That model could translate into agriculture.
An agrochemical company could acquire a startup with:
A promising microbial strain
A novel insecticidal mechanism
An RNA-based pest-control platform
A new herbicide scaffold
A biological delivery system
A computational discovery platform
The larger company would then provide the capital, regulatory expertise, manufacturing capabilities and global distribution required to move the technology toward commercialization.
One area where the comparison is particularly interesting is RNA technology.
In pharmaceuticals, companies are investing heavily in genetic medicines and RNA-based platforms.
In agriculture, RNA interference and related approaches have attracted attention as potential tools for controlling pests and diseases.
The technological challenge is not simply discovering an RNA sequence.
The bigger challenge can involve:
Target selection → RNA stability → delivery → uptake → field performance → environmental behavior
A specialized startup may solve one or more of these problems.
A large agrochemical company could potentially acquire that platform rather than spend years rebuilding the expertise internally.
The biologicals market provides another potential target area.
Agricultural biologicals can include microbial products, biostimulants, biopesticides and other biologically derived solutions.
However, the sector remains fragmented.
Large crop-science companies can face difficulties identifying which smaller platforms have the scientific foundation, manufacturing scalability and field performance required for global commercialization.
A Lilly-style acquisition model could focus on identifying companies where the underlying technology has broader applications than the initial product.
For example, a microbial platform capable of producing one successful biopesticide might also generate additional products targeting other pests or crops.
That platform value can justify a higher acquisition price than a single-product valuation would suggest.
Lilly's Ajax strategy also highlights the increasing importance of computational discovery.
Ajax combined structural biology with computational structure-based drug discovery to design selective JAK2 inhibitors.
The agricultural equivalent is the use of computational tools to identify new chemical structures, optimize selectivity and predict biological activity before large-scale laboratory and field testing.
For agrochemicals, computational platforms could potentially help companies:
Identify new modes of action
Design novel active ingredients
Optimize potency
Improve selectivity
Predict physicochemical properties
Screen large chemical libraries
Reduce experimental cycles
This creates another category of acquisition target.
The company being acquired does not need to have a commercial pesticide.
Its most valuable asset could be the discovery engine itself.
Kelonia offers another strategic lesson.
Its technology is designed to deliver genetic material into T cells inside the body, potentially eliminating some of the complexity associated with conventional cell therapy manufacturing.
Agriculture has a comparable challenge: delivery.
A new biological or nucleic-acid-based pesticide is only useful if the active material can reach its target under real field conditions.
That makes delivery technologies potentially valuable acquisition targets.
For example, a platform that improves:
Leaf penetration
Root uptake
Pest-specific delivery
Environmental stability
Controlled release
Protection from degradation
could potentially be applied across multiple agricultural products.
The delivery platform could therefore be worth more than any individual formulation built on top of it.
Lilly's use of milestone-based consideration also provides a useful financial model.
The Ajax deal, for example, allows shareholders to receive up to $2.3 billion, including payments tied to clinical and regulatory milestones.
Kelonia's transaction similarly includes upfront consideration and additional payments linked to clinical, regulatory and commercial milestones.
Agrochemical companies could use similar structures.
Instead of paying the entire potential value of an early-stage technology immediately, an acquirer could divide consideration according to development milestones.
For example:
Upfront payment → regulatory milestone → field-performance milestone → registration → commercial milestone
This approach allows the buyer to share some development risk with the seller.
Smaller agricultural innovators often struggle with the expensive transition from laboratory discovery to global commercialization.
A technology may work under controlled conditions but require years of:
Field trials
Toxicology testing
Environmental assessments
Regulatory submissions
Formulation optimization
Manufacturing scale-up
A large agrochemical company already has much of this infrastructure.
Acquisition can therefore create value by connecting small-company innovation with large-company execution.
This is essentially the model Lilly is applying to biotechnology.
There are important differences.
Drug development is heavily driven by clinical endpoints and regulatory milestones.
Agricultural products must perform across multiple crops, geographies, climates and pest populations.
A pesticide that performs well in a laboratory may fail in the field because of weather, soil conditions, application methods or resistance.
That makes field validation particularly important.
An agrochemical acquisition strategy should therefore place greater emphasis on real-world performance data before assigning a high valuation to an early technology.
The need for this model is increasing as the industry becomes more difficult to innovate in.
Discovering a completely new conventional active ingredient can require enormous investment and long development timelines.
At the same time, regulatory requirements are becoming more demanding.
This makes alternative technologies increasingly attractive.
Biologicals, RNA-based solutions, precision delivery and computational discovery could potentially create new pathways for innovation without relying entirely on the traditional small-molecule pipeline.
The companies that build portfolios across these technologies may have greater strategic flexibility.
Lilly's acquisition spree also demonstrates the value of diversification.
Its 2026 acquisitions have covered areas including inflammation, genetic medicine, oncology, neuroscience and infectious diseases.
The strategy reduces dependence on one scientific hypothesis.
Agrochemical companies could adopt a similar approach.
Instead of making one large bet on a single next-generation pesticide technology, a company could build a portfolio consisting of:
25% biologicals
20% RNA and genetic approaches
20% novel chemistry
15% delivery technologies
10% computational discovery
10% formulation and precision application
The exact allocation would depend on the company's existing capabilities, but the principle is important: innovation risk can be managed at the portfolio level.
Perhaps the most important lesson from Lilly is that acquisition value should not be measured solely by the lead product.
The stronger question is:
What else can this technology create?
If a startup has one promising pesticide, its value may depend heavily on that product's registration and commercial success.
If the startup has a platform capable of producing multiple active ingredients or biological products, the strategic value can be much larger.
That is the same reason Lilly has been willing to pay billions for companies whose lead programs are still in development.
The buyer is paying for future optionality.
Traditional agricultural M&A has often focused on commercial portfolios, geographic expansion and established product lines.
The next phase could increasingly focus on technology.
Potential acquisition categories could include:
Companies developing completely new biological mechanisms could become especially valuable as resistance increases.
RNA platforms could provide new approaches to pest and disease control.
Microbial and biological platforms capable of generating multiple products could attract strategic buyers.
AI and computational chemistry companies could accelerate active-ingredient discovery and optimization.
Technologies that improve where, when and how an agricultural active reaches its target could increase efficacy while reducing application requirements.
New adjuvants, encapsulation systems and delivery technologies could help reduce environmental impact while maintaining performance.
Lilly's 2026 strategy suggests five principles that could be adapted to agriculture.
First, acquire differentiated science rather than simply buying revenue.
Second, target platforms that can generate multiple future products.
Third, use milestone-based structures to manage development risk.
Fourth, integrate startup technology with the acquiring company's regulatory, manufacturing and commercial infrastructure.
Fifth, maintain a diversified portfolio so that failure of one technology does not undermine the entire innovation strategy.
These principles could be particularly valuable as agricultural companies face rising pressure to deliver new solutions while controlling R&D costs.
Companies such as Bayer, Syngenta, BASF and Corteva already maintain substantial internal research organizations.
The question is not whether they should abandon internal R&D.
It is whether internal R&D should be combined with systematic external innovation acquisition.
Lilly's experience suggests that the two approaches can reinforce each other.
Internal teams understand the company's customers, regulatory infrastructure and commercial requirements.
External startups can provide unconventional scientific ideas and technologies that may be difficult to develop inside a large organization.
The combination can potentially shorten the path from discovery to market.
Eli Lilly's 2026 biotechnology acquisition spree offers more than a pharmaceutical M&A story.
It provides a potential blueprint for how other science-intensive industries can approach innovation.
Lilly has spent billions acquiring specialized biotechnology companies and platforms across oncology, genetic medicine, inflammation, neuroscience and infectious disease. Its reported $13.3 billion in 2026 business-development payments through June demonstrates the scale of the strategy.
For agrochemical companies, the lesson is not to replicate Lilly's spending.
It is to replicate the logic behind the spending.
The next generation of agricultural innovation may come from small companies working on RNA, biologicals, computational chemistry, delivery systems or entirely new modes of action.
Large agrochemical companies already possess the regulatory, manufacturing and distribution capabilities needed to commercialize those technologies.
The strategic opportunity is to connect the two.
Instead of asking only which pesticide a startup has developed, agricultural companies could increasingly ask a more important question:
What innovation platform could this company bring into our portfolio—and how many future agricultural products could that platform generate?
That shift from product acquisition to technology acquisition could become one of the most important changes in agrochemical business development over the next decade.
Featured Product
Found this useful?
Continue Reading
Ross Levine's Memorial Sloan Kettering research helped anchor Ajax Therapeutics' scientific origins, providing the JAK2 biology that ultimately led to a clinical-stage drug and Lilly's potential $2.3 billion acquisition.
Braskem's substantial 2025 revenue base underscores the company's importance within Brazilian agricultural and industrial feedstock supply chains
Clariant's planned CFO succession from Bill Collins to Oliver Rittgen demonstrates how structured leadership handovers can preserve financial continuity during a challenging specialty chemicals cycle.
